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Abstract
Background: In patients with acute coronary syndrome (ACS), reduced left ventricular ejection fraction (LVEF)
is a known marker for increased mortality. However, the relationship between LVEF measured during index ACS
hospitalization and mortality and heart failure (HF) within 1 year are less well-defined.
Methods: We performed a retrospective analysis of 445 participants in the IMMEDIATE Trial who had LVEF
measured by left ventriculography or echocardiogram during hospitalization.
Results: Adjusting for age and coronary artery disease (CAD) history, lower LVEF was significantly associated with
1-year mortality or hospitalization for HF. For every 5 % LVEF reduction, the hazard ratio [HR] was 1.26 (95 % CI 1.15,
1.38, P < 0.001). Participants with LVEF < 40 % had higher hazard of 1-year mortality or HF hospitalization than those
with LVEF > 40 (HR 3.59; 95 % CI 2.05, 6.27, P < 0.001). The HRs for the association of LVEF with the study outcomes
were similar whether measured by left ventriculography or by echocardiography, (respectively, HR 1.32; 95 % CI 1.
15, 1.51 and 1.21; 95 % CI 1.106, 1.35, interaction P = 0.32) and whether done within 24 h or not within 24 h
(respectively, HR 1.28; 95 % CI 1.10, 1.50 and 1.23; 95 % CI 1.10, 1.38, interaction P = 0.67).
Conclusions: Among patients with ACS, lower in-hospital LVEF is associated with increased 1-year mortality or
hospitalization for HF, regardless of the method or timing of the LVEF assessment. This has prognostic implications
for clinical practice and suggests the possibility of using various methods of LVEF determination in clinical research.
Keywords: Acute coronary syndromes, Glucose-insulin-potassium, Left ventricular ejection fraction, Death,
Hospitalization from heart failure
Background
Acute coronary syndrome (ACS) remains a leading
cause of death in the United States [1]. Reduced left
ventricular ejection fraction (LVEF), measured with
standardized methods at 30 days following ACS, is an
established marker for poor clinical outcome [2, 3],
but the relationships between LVEF measured during
the index ACS hospitalization and clinical outcomes
are less well-defined. Moreover, LVEF measured by
noninvasive transthoracic echocardiography and inva-
sive left ventriculography has been used to risk stra-
tify patients with ACS [4–7], but the best modality
and timing of measurement of in-hospital LVEF are
not known.
In the IMMEDIATE (Immediate Myocardial Metabolic
Enhancement During Initial Assessment and Treatment
in Emergency care) Trial [8], participants with suspected
ACS who received intravenous glucose-insulin-potassium
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(GIK) had generally fewer serious outcomes at 1 year
than those treated with placebo, but the difference
did not reach statistical significance [9]. However,
among those presenting with ST elevation myocardial
infarction (STEMI), the composite outcomes of cardiac
arrest or 1-year mortality, and of cardiac arrest, mortality,
or hospitalization for heart failure (HF), were significantly
reduced [9]. Long-term outcomes based on LVEF rou-
tinely measured during ACS hospitalization, in general,
and in the context of GIK, have not been studied. Using
data from the IMMEDIATE Trial, we sought to determine
if LVEF measured during ACS hospitalization was asso-
ciated with the 1-year composite outcome of all-cause
mortality or hospitalization for HF.
We hypothesized that reduced in-hospital LVEF
would be a marker of increased risk of death or HF
hospitalization at 1 year. As a secondary goal, we tested
whether in-hospital LVEF was higher among IMME-
DIATE Trial participants randomized to GIK as com-
pared to those randomized to placebo.
Methods
Study sample
This study analyzed a subset of data on participants
enrolled in the IMMEDIATE Trial [8, 10], a randomized,
placebo-controlled, double-blind clinical effectiveness
trial of GIK conducted from December 2006 through July
2011, in which paramedics, aided by electrocardiograph-
based decision support, enrolled 871 patients aged ≥
30 years with high probabilities of ACS. Participants
were given either GIK (30 % glucose, 50 U/L of
regular insulin, and 80 mEq of KCl/L) intravenously
at 1.5 mL/kg/h for 12 h, or identical-appearing pla-
cebo. This investigation included the subset of parti-
cipants who had their LVEF measured during their
index hospitalization by left ventriculography or echo-
cardiography [8, 10].
Inclusion and exclusion criteria from the IMMEDIATE Trial
Screened patients included all those transported by emer-
gency medical services (EMS) in response to a 9-1-1 call
for symptoms suggestive of ACS who were ≥ 30 years
of age and had an out-of-hospital electrocardiogram
(ECG) performed. Inclusion was based on paramedics’
clinical assessment of a patient likely having ACS, supple-
mented by decision support by the electrocardiograph-
based Acute Cardiac Ischemia Time-Insensitive Predictive
Instrument (ACI-TIPI) and Thrombolytic Predictive
Instrument (TPI). Patients were candidates for enroll-
ment if the ACI-TIPI prediction of ACS was 75 % or
higher, if STEMI was detected by the TPI, and/or the
patient met local standards for EMS identification of
STEMI [10]. Patients were excluded if they had a lan-
guage barrier or impaired reasoning, were prisoners or
pregnant, or had clinically significant rales (Killip Class 3
or 4 HF) [8, 10].
In addition, a National Institutes of Health appointed
Data Safety Monitoring Board oversaw enrollment to
ensure safe and ethical study conduct throughout the
trial. Informed consent was obtained from all patients in
accordance with the Exception from Informed Consent
Requirements for Emergency Research per the Code of
Federal Regulations 21 CFR 50.24 and included commu-
nity consultation, institutional review board approval
from all sites, assent from patients prior to randomization,
and written consent once stabilized at the hospital [11].
The Coordinating Center’s IRB at Tufts Medical
Center provided approval for the overall trial along with
all participating sites (University of Texas Southwestern
Medical School, Dallas; Cambridge Health Alliance,
Cambridge, Massachusetts; Alaska Regional Hospital,
Anchorage; University of New Mexico School of Medicine,
Albuquerque; Medical College of Wisconsin, Milwaukee;
Medical Center of Central Georgia, Macon; Regions
Hospital EMS, St. Paul, Minnesota; Avera Medical Group,
Sioux Falls, South Dakota; Penn State Hershey Medical
Center, Hershey, Pennsylvania; Emerson Hospital, Concord,
Massachusetts; St Joseph Medical Center, Bellingham,
Washington; Texas Tech University Health Sciences
Center, El Paso; Yale New Haven Hospital, Connecticut)
Data collection
Data were collected by trained study staff. They were
instructed to record LVEF as measured by cardiac
catheterization; if the catheterization was not done, and
LVEF was available by echocardiogram, this was recorded.
The dates and times of echocardiograms were not rou-
tinely recorded, so medical records were reviewed to
obtain them where possible. Based on emergency depart-
ment (ED) presentation date and dates of LVEF measure-
ment by left ventriculography or echocardiography, we
classified a participant’s LVEF as “early” (within 24 h of
ED presentation), or “not early” if measured more than
24 h after ED presentation. We could not find the date
and time of LVEF measurement for 94 out of 445 parti-
cipants; for this study we assigned them to the not early
group, as the majority (92) had echocardiograms, and our
search showed that the majority of the echocardiograms
were done more than 24 h after ED presentation.
Data analysis
Statistical analyses were performed using R, version
2.15.2. Tests were two-sided, using alpha ≤ 0.05 as statis-
tical significance. Comparison of means of in-hospital
LVEF between the GIK and placebo groups, between
early and not early LVEF measurement, and between
catheterization and echocardiogram measurement all
used two-sample student t-tests. Just for the Kaplan–
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Meier survival curves, they were plotted for participants
with LVEFs in normal (55–70 %), mildly abnormal
(40–54 %), moderately abnormal (25–39 %) and severely
abnormal (<25 %) categories. Cox proportional hazards
models were used to estimate univariate hazard ratios
(HRs) for LVEF associated with the composite outcome of
death or hospitalization for HF. Based on clinical and
statistical significance in those analyses, we chose candi-
date variables for possible inclusion in a multivariable
model to estimate adjusted HRs for the composite out-
come of death or hospitalization for HF at 1 year. Using
the final adjusted model, we also tested for dichotomous
variables of timing of LVEF (early vs. not early) and
the measurement method (catheterization vs. echocar-
diogram). Two-way interactions between LVEF and timing
(early vs. not early) were tested in the Cox proportional
hazard model of the composite outcome, adjusting for age
and coronary artery disease (CAD). A similar analysis was
done to test the two-way interaction between LVEF and
test method (catheterization vs. echocardiogram). We
checked assumptions needed for proportional hazards




Table 1 shows demographic and clinical features of
participants having the composite outcome of death
or hospitalization for HF at 1 year (n = 52) and those
who did not (n = 393). Participants with the composite
outcomes were older and more frequently had medical
histories of CAD, HF, diabetes, hypertension, stroke, and
hyperlipidemia. Rates of acute myocardial infarction were
similar in both groups, but those participants that had the
composite outcome presented with a significantly higher
Killip Class. Please see Appendices below.
Data on LVEF measured by left ventriculography or
echocardiography during the index hospitalization
were available for 445 of 871 study participants. There
were significant differences in baseline demographics
and clinical characteristics of participants with and
without in-hospital LVEFs recorded. Of participants
with in-hospital LVEF measured, 92.6 % had con-
firmed diagnoses of ACS, compared with 33.1 %
among those without measured LVEF. There were no
significant differences between characteristics of par-
ticipants who had in-hospital LVEF recorded by left
ventriculography vs. echocardiography. For 248 parti-
cipants, LVEF was measured early (219 [80.1 %] by
catheterization), defined as measurement within 24 h
of presentation, and for 197 participants, the LVEF
measurement was performed not early (54 [19.7 %]
by left ventriculography).
Univariate models of LVEF and outcomes
Participants with the lowest LVEF had the lowest survival
and the greatest incidence of composite outcomes (Fig. 1).
Univariate Cox proportional hazard models were used to
identify factors associated with the composite outcome
(Table 2). A reduction of LVEF by 5 % decrements was
significantly associated with higher hazards of death or
hospitalization for HF over 1 year (HR = 1.31, 95 % CI:
1.20–1.45, P < 0.001). Also significant was age, expressed
in 10-year increments (HR = 1.79, 95 % CI: 1.44–2.24, P <
0.001), prior CAD (HR = 4.46, 95 % CI: 2.47–8.04, P <
0.001), HF (HR = 3.56, 95 % CI: 1.86–6.79, P < 0.001),
diabetes (HR = 1.88, 95 % CI: 1.06–3.34, P = 0.030), hyper-
tension (HR = 2.17, 95 % CI: 1.12–4.23, P = 0.022), and
stroke (HR = 2.56, 95 % CI: 1.20–5.43, P = 0.015).
Multivariable models of LVEF and outcomes
Multivariate Cox models were used to better characterize
the association of LVEF with the composite outcome. In
stepwise regression, candidate parameters for inclusion
included LVEF expressed by 5 % decrements; age, sex,
history of CAD, HF and diabetes. The model that had the
lowest akaike information criteria (best fit) following the
selection process included only LVEF, age, and CAD. The
C statistic (which is equivalent to the receiver-operating
characteristic (ROC) curve area) for that model is 0.805
(SE = 0.04).
The effect of 5 % lower LVEF on 1-year death or
hospitalization for HF remained statistically significant
after adjusting for age and history of CAD (HR = 1.26;
95 % CI: 1.15–1.38, P < 0.001) when LVEF was used as a
continuous variable. When LVEF was tested as a binary
variable and dichotomized, participants with LVEF < 40 %
had higher hazard of 1-year mortality and hospitalization
for HF compared to participants with LVEF ≥ 40 %, after
adjusting for age and history of CAD (HR = 3.59; 95 % CI:
2.05–6.27, P < 0.001). The proportional hazard assumption
was not violated. Separating the composite outcome into
its components, reductions of LVEF by 5 % decrements
were also significantly associated with higher hazard of
death and hospitalization for HF when adjusted for age
and history of CAD (HR = 1.18; 95 % CI: 1.06–1.32, P =
0.002; and HR = 1.37; 95 % CI: 1.18–1.58, P < 0.001,
respectively) (Table 2).
The HRs for the association of LVEF with the study
outcomes were similar whether measured by left ventri-
culography or by echocardiography, (respectively, HR =
1.32; 95 % CI 1.15, 1.51 and 1.21; 95 % CI 1.106, 1.35)
and whether done within 24 h or not within 24 h
(respectively, HR = 1.28; 95 % CI 1.10, 1.50 and 1.23;
95 % CI 1.10, 1.38). Tests for interactions of LVEF and
measurement method and LVEF and timing did not reach
significance (Table 3). Controlling for method of LVEF
measurement (left ventriculography vs. echocardiography)
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or timing of measurement (early vs. not early) did not
alter the association of LVEF with the outcome (Table 4).
Additionally, while having an echocardiogram (vs. left
ventriculography) and being not early (vs. early) were
associated with the 1-year outcome, neither was statis-
tically significant.
Sensitivity analyses were performed in which we re-
estimated HRs for LVEF, adjusting not only for already
specified covariates age and CAD history, but also for
sex, HF history, and diabetes. Reductions of LVEF by
5 % were significantly associated with higher hazard of
the 1-year composite outcome (HR = 1.25; 95 % CI:
1.14–1.38, P < 0.001). Also, the HRs for the association
of LVEF with the study outcome when measured by left
ventriculography vs. by echocardiography, and for when
measured early vs. not early, were similar. Finally, we
studied the association of the IMMEDIATE Trial treat-
ment, GIK vs. placebo, on in-hospital LVEF, stratified by
method (catheterization vs. echocardiogram) and timing
(early vs. not early. There was a trend toward higher in-
hospital LVEF among those receiving GIK. When mea-
sured by echocardiography alone, median LVEF with
Table 1 Baseline characteristics of participants with LVEF and outcomes (N = 445)
Variables Participants with neither death nor hospitalization
for HF at 1 year N = 393
Participants with death or hospitalization
for HF at 1 year N = 52
Age (mean ± SD, years) 61 ± 12.1 (393) 71 ± 13.0 (52)
Gender, % Male 75.6 (297) 69.2 (36)
White race (vs. non- White race) 86.7 % (341) 88.5 % (42)
Body Mass Index, (mean ± SD, units) 28.9 ± 6.3 (372) 27.9 ± 6.0 (42)
Time from onset of symptoms to treatment (minutes)
Mean ± SD, 146.8 ± 206.4 (353) 111.7 ± 109.3 (37)
median < IQR > 78 < 50.0–140.0 > 65 < 40.0–145.0 >
Chief Complaint on Presentation
Chest Pain 91.8 % (361) 84.6 % (44)
Medical History, % (n)
CAD (MI, PCI or CABG) 30.8 % (121) 69.2 % (36)
Heart Failure 6.7 % (25) 23.1 % (12)
Diabetes Mellitus 21.1 % (83) 34.7 % (18)
Hypertension 62.3 % (245) 78.8 % (41)
Stroke 5.9 % (23) 15.4 % (8)
Hyperlipidemia 46.8 % (184) 65.4 % (34)
Hospital Reperfusion Treatment, %(n)
PCI 73.8 % (290) 59.6 % (31)
Thrombolytic therapy 0.8 % (3) 9.6 % (5)
CABG 5.1 % (20) 7.7 % (4)
Confirmed Diagnosis, % (n)
Acute Myocardial Infarction 80.4 % (316) 78.8 % (41)
Killip Class
1 76.1 % (299) 51.9 % (27)
2 1.8 % (7) 1.3 % (7)
3 0.5 % (2) 3.8 % (2)
4 2.0 % (8) 9.6 % (5)
Unstable Angina 12.7 % (50) 9.6 % (5)
ECG based findings
ST Elevation on Presentation (ECG) 70.8 % (264) 66.0 % (33)
ACI-TIPI score, (Mean ± SD) 80.7 ± 17.6 (386) 84.8 ± 11.2 (49)
LVEF in %, Median (IQR) 50 (40,60) 35 (25,45)
GIK (vs. Placebo) 47.6 % (187) 38.5 % (20)
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GIK 50 % vs 45 % with placebo (P = 0.08). When mea-
sured by either echocardiography or catheterization,
the median LVEF with GIK was 50 % vs 45 % with
placebo (P–0.07) (Table 5).
Discussion
In this post hoc analysis of IMMEDIATE trial parti-
cipants who had in-hospital LVEF assessment we
demonstrate that in-hospital LVEF for patients with ACS
can identify patients at risk for death or HF hospitalization
within 1 year. Our results do not favor left ventriculo-
graphy or echocardiography as a preferred modality for
LVEF measurement; as the predictive ability of LVEF was
similar for both modalities. These results also do not
support a need for LVEF assessment within 24 h of pre-
sentation. These results have practical importance for the
care of patients with ACS because our data suggest that
assessment of LVEF measured at any point in the
hospitalization can be used to predict patients at risk of
death or hospitalization for HF within 1 year.
In-hospital LVEF assessment is not routinely performed
in ACS patients. One study demonstrated over 40.8 % of
patients with non-ST elevation myocardial infarction did
not have an LVEF assessment [12, 13], and the percentage
of patients getting LVEF measurement has steadily in-
creased in the last two decades [14, 15]. LVEF is superior
to end systolic volume index and infarct size in predicting
6-month mortality after myocardial infarction [2]. The
presence of LV dysfunction on baseline left ventriculo-
graphy in patients enrolled in the HORIZONS–AMI trial
who underwent primary PCI was a powerful predictor of
early and late mortality irrespective of the extent of coro-
nary artery disease [7]. The age, creatinine and ejection
fraction score (ACEF), as proposed by J H Lee et al. may
Fig. 1 Kaplan–Meier plot for categories of LVEF
Table 2 Unadjusted and multivariable-adjusted Cox
proportionate hazard models for composite outcomes
(death and hospitalization for HF) by LVEF measured in-hospital
(N = 445, no of events = 52)
Unadjusted cox proportional hazard model
Variables HR (95 % CI) P-value
LVEF/5 % decrease 1.31 (1.20,1.45) < 0.001
Age/10 years increase 1.79 (1.44, 2.24) < 0.001
Gender, Male 1.37 (0.41, 1.32) 0.23
White race (nonwhite race reference) 1.13 (0.48, 2.65) 0.77
Body Mass Index 0.97 (0.92, 1.02) 0.32
Time from onset of symptoms to treatment* 0.98 (0.99, 1.00) 0.33
Chief complaint on presentation
Chest pain 0.53 (0.23, 1.12) 0.10
Out of Hospital ECG ST-Elevation 0.84 (0.47, 1.50) 0.55
ACI-TIPI Score 1.02 (0.99, 1.04) 0.12
Medical history
CAD (MI, PCI or CABG) 4.46 (2.47, 8.04) < 0.001
Heart Failure 3.56 (1.86, 6.79) < 0.001
Diabetes 1.88 (1.06, 3.34) 0.03
Hypertension 2.17 (1.12, 4.23) 0.02
Stroke 2.56 (1.20, 5.43) 0.02
Multivariable adjusted cox proportional hazard models
Variables HR (95 % CI) P value
Outcome (Composite)
LVEF/5 % lower (combined) 1.26 (1.15, 1.38) < 0.001
Age/10 years Increase 1.73 (1.38, 2.18) < 0.001
History of CAD (MI, PCI, or CABG) 2.97 (1.62, 5.43) < 0.001
Outcome (Death)
LVEF/5 % lower (combined) 1.18 (1.06, 1.32) 0.002
Age/10 years Increase 1.94 (1.47, 2.55) <0.001
History of CAD (MI, PCI, or CABG) 3.56 (1.69, 7.49) < 0.001
Outcome (Hospitalization for HF)
LVEF/5 % lower (combined) 1.37 (1.18, 1.58) < 0.001
Age/10 years Increase 1.35 (0.95, 1.91) 0.09
History of CAD (MI, PCI, or CABG) 2.27 (0.93, 5.56) 0.007
Table 3 Association of LVEF with composite outcome, stratified





LVEF- by catheterization/5 % lowera 1.32 (1.15, 1.51) 0.32
LVEF- by echocardiogram/5 % lowera 1.20 (1.06, 1.35)
LVEF- early/5 % lowera 1.28 (1.10, 1.50) 0.67
LVEF- not early/5 % lower* 1.23 (1.10, 1.38)
aAdjusted for age and history of CAD
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be used to stratify the 1-year mortality risk in 30-day
survivors who underwent percutaneous coronary inter-
vention (PCI) after acute myocardial infarction [16]. In
spite of optimal medical therapy and clinically driven
percutaneous coronary intervention (PCI), LVEF and
angiographic burden of disease at baseline retain prog-
nostic importance for patients aggressively treated for
stable CAD [17].
Our study, which featured the full spectrum of ACS
presentations, suggests that useful information can be
obtained by measuring LVEF by either left ventriculo-
graphy or echocardiography at any time prior to hospital
discharge. These findings have important implications
for clinical effectiveness research, because we demonstrate
the utility of collecting data from clinically-indicated and
performed LVEF assessments in large multicenter clinical
trials as a means to define the risk of longitudinal cardiac
outcomes. If substantiated as a research tool, this finding
has the potential to reduce the need for core lab LVEF
assessments, which can be quite costly.
In the IMMEDIATE Trial, GIK did not significantly
reduce the primary endpoint of progression of unstable
angina to AMI, but it did significantly reduce the com-
posite endpoint of cardiac arrest or mortality, and in the
biological mechanism cohort, the median infarct size
measured by sestamibi SPECT imaging at 30 days was
80 % lower in the GIK compared to the placebo group.
Further, there was a trend for better LVEF measured by
SPECT imaging at 30 days with GIK [8]. Our study also
showed that GIK had a trend toward improved in-hospital
LVEF when compared to placebo especially when mea-
sured by echocardiography. Future well-powered studies
will be required to further delineate the effect of GIK on
infarct size and long-term left ventricular function.
Our study has several limitations. It is a retrospective
analysis using data from a prospective randomized
controlled trial on a subset with 445 participants who
had LVEF measured by echocardiogram or cardiac
catheterization. While the sample is not large, we had 52
composite outcomes in the group. The study cohort
includes patients with high-risk ACS. The LVEF was
measured by two different modalities at slightly different
times, which could introduce bias since the LVEF mea-
sured by left ventriculography was during revascula-
rization and LVEF measured by echocardiography was
primarily obtained prior to hospital discharge. However,
our study showed that the methodology and the timing
of the LVEF measurement did not matter. The study
cannot compare the in-hospital LVEF measurement with
an assessment made by a core lab, and hence we cannot
say that clinical LVEF results necessarily give the same
information as measurements made by a core laboratory.
However, we did find that LVEF measured in the hospital
and not by a core laboratory was significantly associated
with 1-year outcomes of death and HF hospitalization.
Conclusion
Lower in-hospital LVEF is associated with higher rates
of 1-year mortality and hospitalization from HF in pa-
tients hospitalized with ACS, regardless of the method
or timing of LVEF assessment. This has prognostic
implications for clinical practice and suggests the possi-
bility of using various methods of LVEF determination
in clinical research.
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aEarly when the LVEF was measured within 0 days of ED arrival
bNot early when LVEF was measured 1 or more days after ED arrival or with
unknown dates
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